The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

ACRS FINANCIAL STATEMENTS

Aclaris Therapeutics Inc — balance sheet, income statement and cash flow trends

ACRSAclaris Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-150 M-100 M-50 M0202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue8.2 M $Gross Profit7.9 M $ · 96%Operating Income-86.3 M $ · -1050%Pre-tax Income-75.7 M $ · -921%Net Income to Owners-75.7 M $ · -921%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue8.2 M $-51.0%
Gross Profit7.9 M $+188.5%
Operating Income-86.3 M $—
EBITDA-75.1 M $—
Net Income to Owners-75.7 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0100 M200 M300 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets179.7 M
  • Equity124.6 M $74%
  • Current Liabilities28.2 M $17%
  • Long-term Liabilities15.6 M $9%

Key Figures

YoY change
Total Assets179.7 M $-5.0%
Total Liabilities55.1 M $-4.0%
Total Equity124.6 M $-5.4%
Cash & ST Investments91.6 M $-8.3%
Total Debt——
Net Debt-19.2 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-50 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-100 M-50 M0-80.2 M $Operating-27.4 M $Investing110.1 M $Financing2.5 M $Net Change

Key Figures

YoY change
Operating Cash Flow-80.2 M $—
Capital Expenditures131 K $-99.6%
Free Cash Flow-80.3 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on ACRS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.